复星医药(02196)今日盘中大涨5.01%,引发市场关注。
据了解,该公司控股子公司复宏汉霖近期取得了多项业务进展,有望助力母公司复星医药股价上涨。首先,复宏汉霖与Dr. Reddy's就在研达雷妥尤单抗生物类似药HLX15达成欧美授权合作,为其加速全球布局奠定基础。此外,复宏汉霖自主研发的新药斯鲁利单抗注射液也获欧盟批准上市,拓展了公司创新药产品线。
不过,值得注意的是,今年1月份复星医药原计划私有化复宏汉霖的方案未获批准。为增强投资者信心,公司决定未来6个月内以不低于3亿元回购A股,同时回购不超过5%的H股。分析人士预计,此举也可能是股价大涨的推手之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.